Published in final edited form as:

Curr Addict Rep. 2016 September ; 3(3): 332–342. doi:10.1007/s40429-016-0113-z.

Brain mechanisms of Change in Addictions Treatment: Models, Methods, and Emerging Findings

Tammy Chung, Ph.D.¹, Antonio Noronha, Ph.D.², Kathleen M. Carroll, Ph.D.³, Marc N. Potenza, M.D., Ph.D.⁴, Kent Hutchison, Ph.D.⁵, Vince D. Calhoun, Ph.D.⁶, John D. E. Gabrieli, Ph.D.⁷, Jon Morgenstern, Ph.D.⁸, Sara Jo Nixon, Ph.D.⁹, Bruce E. Wexler, M.D.¹⁰, Judson Brewer, M.D., Ph.D.¹¹, Lara Ray, Ph.D.¹², Francesca Filbey, Ph.D.¹³, Timothy J. Strauman, Ph.D.¹⁴, Hedy Kober, Ph.D.¹⁵, and Sarah W. Feldstein Ewing, Ph.D.¹⁶

Tammy Chung: chungta@upmc.edu; Antonio Noronha: anoronha@mail.nih.gov; Kathleen M. Carroll: kathleen.carroll@yale.edu; Marc N. Potenza: marc.potenza@yale.edu; Kent Hutchison: kent.hutchison@colorado.edu; Vince D. Calhoun: vcalhoun@unm.edu; John D. E. Gabrieli: Gabrieli@mit.edu; Jon Morgenstern: jmorgenste@nshs.edu; Sara Jo Nixon: sjnixon@ufl.edu; Bruce E. Wexler: bruce.wexler@yale.edu; Judson Brewer: judson.brewer@umassmed.edu; Lara Ray: laraaray@psych.ucla.edu; Francesca Filbey: francesca.filbey@utdallas.edu; Timothy J. Strauman: tjstraum@duke.edu; Hedy Kober: hedy.kober@yale.edu; Sarah W. Feldstein Ewing: feldstei@ohsu.edu

¹University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, PA 15213, Phone: 412-246-5147, Fax: 412-246-6550

²National Institute on Alcohol Abuse and Alcoholism, 5635 Fishers Lane, Bethesda, MD, Phone: 301-443-7722, Fax: 301-443-1650

³Yale University, 950 Campbell Avenue, MIRECC 151D, West Haven, CT 06516, Phone: 203-932-3869 x7403, Fax: 203-937-3869

⁴Yale University, 34 Park St, New Haven, CT 06519, Phone: 203-974-7356, Fax: 203-974-7366

⁵University of Colorado at Boulder, Muenzinger Psychology, 345 UCB, Boulder, CO 80309, Phone: 303-492-8163

⁶The Mind Research Network, The University of New Mexico, 1 University of New Mexico, Albuquerque, NM 87131, Phone: 505-272-1817, Fax: 505-272-8002

⁷McGovern Institute for Brain Research, Massachusetts Institute of Technology, 43 Vassar Street, Building 46-4033, Cambridge, MA 02139, Phone: 617-253-8946, Fax: 617-324-5311

Correspondence to: Tammy Chung, chungta@upmc.edu; Sarah W. Feldstein Ewing, feldstei@ohsu.edu.

Compliance with Ethics Guidelines

Conflict of Interest

Tammy Chung reports grants from National Institute on Alcohol Abuse and Alcoholism during the conduct of the study. Kathleen M. Carroll reports grants and other fees from CBT4CBT LLC outside of the submitted work. In addition, Dr. Carroll has a patent Copyright issued. Sara Jo Nixon reports grants from NIAAA, during the conduct of the study. Bruce E. Wexler has a patent functionalities of brain-training programs pending. Judson Brewer reports grants from the National Institutes of Health during the conduct of the study and other fees from Claritas MindSciences outside the submitted work. Dr. Potenza reports other fees from Springer, Oxford Press & American Psychiatric Press, fees from Opiant/Lakelight Therapeutics, RiverMend Health, INSYS, Shire, grants from Pfizer, fees from Gambling and legal entities, outside the submitted work.

Antonio Noronha, Kent Hutchison, Vince D. Calhoun, John D. E. Gabrieli, Jon Morgenstern, Lara Ray, Francesca Filbey, Timothy J. Strauman, Hedy Kober, and Sarah W. Feldstein Ewing declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

Cited studies comply with research protections for human and animal subjects, as required by the specific journal in which the study was published.

⁸Northwell Health, 1010 Northern Blvd, Great Neck, NY 11021, Phone: 516-837-1694

⁹McKnight Brain Institute, University of Florida, PO Box 100256, Gainesville, FL 32610, Phone: 352-294-4920

¹⁰Yale University, 34 Park St, New Haven, CT 06519, Phone: 203-974-7339

¹¹University of Massachusetts Medical School, Worcester, MA 01655 and Yale University School of Medicine, New Haven, CT 06515, Phone: 508-856-1632; Fax 508-856-1977

¹²Department of Psychology, University of California at Los Angeles, 1285 Franz Hall, Los Angeles, CA 90095, Phone: 310-794-5383

¹³University of Texas at Dallas Center for Brain Health, 2200 West Mockingbird Lane, Dallas, TX 75235, Phone: 972-883-3204

¹⁴Duke University, 316 Soc-psych Building, Durham, NC 27708, Phone: 919-660-5709

¹⁵Yale University, 1 Church Street, Suite 701, New Haven, CT 06525, Phone: 203-737-5641

¹⁶Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, Phone: 503-418-9604

Abstract

Increased understanding of “how” and “for whom” treatment works at the level of the brain has potential to transform addictions treatment through the development of innovative neuroscience-informed interventions. The 2015 Science of Change meeting bridged the fields of neuroscience and psychotherapy research to identify brain mechanisms of behavior change that are “common” across therapies, and “specific” to distinct behavioral interventions. Conceptual models of brain mechanisms underlying effects of Cognitive Behavioral Therapy, mindfulness interventions, and Motivational Interviewing were discussed. Presentations covered methods for integrating neuroimaging into psychotherapy research, and novel analytic approaches. Effects of heavy substance use on the brain, and recovery of brain functioning with sustained abstinence, which may be facilitated by cognitive training, were reviewed. Neuroimaging provides powerful tools for determining brain mechanisms underlying psychotherapy and medication effects, predicting and monitoring outcomes, developing novel interventions that target specific brain circuits, and identifying for whom an intervention will be effective.

Keywords

neuroimaging psychotherapy; addictive behaviors; translational; alcohol; substance use disorder

Introduction

A critical barrier to progress in improving the magnitude and durability of treatment effects for addictive behaviors involves addressing gaps in knowledge regarding “how” treatment works, and “for whom”, at the level of the brain [1–3]. Increased understanding of brain-based mechanisms of change has potential to revolutionize approaches to behavioral treatment through application of neuroscience principles of learning and motivation to

amplify the effect of “active ingredients” of psychotherapy, identify “common” and “therapy-specific” processes of change, specify brain targets for intervention, optimize dosing and treatment duration, and sustain positive treatment outcomes.

Presentations at the 2015 Science of Change meeting, summarized in the following abstracts, covered conceptual models of brain mechanisms of change for behavioral interventions such as Cognitive Behavioral Therapy [CBT], mindfulness, and Motivational Interviewing [MI]). Opening remarks and keynote speakers discussed how neuroimaging methods can provide important insights into specific brain targets for intervention. Integrating neuroimaging into clinical research, however, involves addressing basic methodologic and analytic challenges. Presentations covered the use of neuroimaging to predict treatment outcomes, to study brain changes that occur during treatment, and potential clinical applications of neuroimaging, for example, in neurofeedback and multi-modal approaches to treatment.

Opening Remarks: Brain imaging as a tool to develop effective alcoholism treatment

Antonio Noronha—This translational meeting brings together the fields of neuroscience and behavioral therapies to improve treatments, particularly for alcohol use disorders (AUDs). A tool such as brain imaging will support the development of more effective behavioral treatments for alcoholism by helping to understand brain-based mechanisms of why some treatments work and also individual differences in response to treatment [4]. Neuropsychological studies of individuals in recovery from alcoholism have revealed a typical profile of functional impairments, which may improve with extended sobriety (see Dr. Nixon’s abstract). In temporal parallel, brain structural changes associated with chronic heavy alcohol use are also reversible with sustained sobriety. Thus, some alcoholics typically endure “incomplete” lesions, and therefore, retain neural tissue with the potential for structural repair and enabling functional repair.

Damage to circuitry in one area can affect distal regions and functions. However, the healthy nodes and systems intersecting with affected circuitries have connections of their own and the potential of “taking over” affected function or compensating for dysfunction. Neural systems affected in alcoholism include frontostriatal, frontocerebellar, and limbic circuitry, and present targets for retraining. For example, functional imaging studies have shown that for alcoholic individuals to perform certain tasks (e.g., spatial working memory), frontal and cerebellar regions are activated, whereas controls activate frontal regions alone. Another interesting potential source for functional enhancement is the coupling of task-activated networks with resting-state activity.

Treatments to repair neural circuitry affected in alcoholism include, for example, the combined use of transcranial magnetic stimulation (TMS) with direct current stimulation (tDCS). Combined TMS and tDCS provide a method to redirect selective regions of brain response to particular tasks or stimuli. In addition, multimodal imaging using diffusion tensor imaging (DTI) to determine the health of white matter microstructure together with functional magnetic resonance imaging (fMRI) for brain activation could assist in identifying brain networks that are viable and potentially supportive of retraining. Retraining the brain and its circuitry to overcome dysfunction is having success in stroke, reading

disability, dyslexia, and traumatic brain injury. Tools such as brain imaging also can be used, for example, in the actual treatment process with circuit retraining and neurofeedback during functional imaging.

Keynote: Neuroimaging and clinical research collaboration to study treatment processes

Kathleen Carroll and Marc Potenza—Our collaborative research program involves systematically testing and refining a model of brain mechanisms of change for empirically validated therapies (cognitive behavioral therapy, contingency management) across a range of addictive disorders. We have been successful in integrating pre- and post-treatment neuroimaging into most of our ongoing randomized clinical trials via use of a range of practical strategies as well as integration of perspectives from multiple disciplines (imaging and neuroscience; addictions treatment and clinical trials; cognitive science; psychopharmacology). Over time, we have refined our paradigms to accommodate the complex nature of this work (see Figure 1), reflecting the complicated and dynamic effects of patient premorbid functioning, effects of chronic substance use, ongoing use of substances, the interplay of common and unique aspects of treatment, treatment exposure and process, and selection of appropriate imaging tasks and analytic strategies. In our model, neural mechanisms of change for CBT are proposed to involve multiple circuits that relate to specific components of the therapy [3]. For example, the acquisition of skills to better control response to internal and external cues associated with craving and addictive behaviors (substance use, gambling) may involve changes in brain circuitry (e.g., dorsolateral prefrontal and anterior cingulate cortices) that may promote more effective decision-making. Alterations in the function of subcortical regions (including within cortical-striatal circuitry) may also be involved given that individuals may learn to exert greater cortical control over motivational drives to participate in addictive behaviors. Our preliminary studies suggest that brain activations in both cortical and subcortical regions underlying cognitive control and reward processing relate prospectively to improved treatment outcomes, with several of our recent studies suggesting that changes in brain function are associated with indicators of exposure to specific elements of CBT and contingency management. These findings provide insight into the neural mechanisms of CBT and hence improvements that may enhance its efficacy and durability, as well as prove useful to the development of novel targets and treatments.

Integrating Neuroimaging Into Randomized Controlled Trials: Methodological and Analytical Issues

Kent Hutchison—The integration of randomized controlled trials (RCTs) with neuroimaging offers scientists the opportunity to test key theoretical constructs linking treatment, mechanistic targets in the brain, and behavioral outcomes. A successful integration of neuroimaging in the context of RCTs can only be accomplished with a detailed theoretical model linking the treatment to mechanisms in the brain and more distal behavioral outcomes. As an example, a mechanistic model of Mindfulness Based Relapse Prevention (MBRP) illustrates the integration of neuroimaging into an RCT (Figure 2). In this model, MBRP, compared to Relapse Prevention (RP), is hypothesized to have effects through two mechanisms: one mechanism involves reducing neuroinflammation, which then increases connectivity of cognitive control circuitry (resting state); and the other involves

mitigating epigenetic modifications due to chronic alcohol exposure, which then impacts the reward network (cue reactivity). From a methodological perspective, the challenge is to integrate neuroimaging methods with RCT design considerations. RCTs usually involve samples sizes of >60 patients per group (medium to small effects) and follow-ups, typically at 3- and 6-months post treatment. fMRI tasks need to be selected to test the specific MBRP mechanisms involving cognitive control and reward sensitivity, and reliably activate relevant circuitry. Neuroimaging sessions need to occur such that the treatment has adequate time to impact the brain mechanism, but prior to when the treatment is expected to impact behavioral outcomes, to establish temporal precedence of the mechanisms. Potential drawbacks to including neuroimaging in an RCT involve additional exclusionary criteria, which complicates sample ascertainment, imaging costs, increased Type I error, and the need for analytic methods that reduce neuroimaging data in a way that allows for it to be used in traditional statistical models of treatment effects. While integrating neuroimaging into RCTs is definitely challenging, the potential scientific gains of understanding more precisely how a treatment leads to behavior change are worth the effort.

Maximizing information in brain imaging studies: dynamics, prediction, data-fusion, deep learning, data capture

Vince D. Calhoun—The brain imaging data collected to date encodes an incredible amount of information that we are only beginning to understand. Emerging approaches have begun to yield useful information from these data that were not conceived of when it was collected. For example, the field has fairly recently embraced the concept of whole-brain time-varying connectivity (i.e. the chronnectome [5]). As an example, the resting brain states of individuals using different substances such as alcohol, marijuana, or smoking, manifest differently [6]. Secondly, there is growing interest in using brain imaging data to make predictions at the level of the individual subject ranging from mild traumatic brain injury [7] to schizophrenia [8]. Thirdly, it is becoming increasingly clear that multi-modal data fusion is able to provide more information for individual subjects by exploiting the rich multimodal information that exists, rather than an analysis of each modality alone. The complexity of the human brain coupled with the incomplete measurement provided by existing imaging technology makes multimodal fusion essential in order to increase our ability to characterize disease, mitigate against misdirection and hopefully provide a key to finding the missing link(s) in complex mental illness [9]. Fourthly, approaches based on more complex models, so called deep-learning, have shown substantial improvements in certain domains. These approaches also show great promise for identifying hidden disease related patterns in mental illness [10] or identifying the translation between brain structure and brain function [11]. And lastly, there is a huge focus on sharing neuroimaging data [12]. As new tools come online for advanced data capture, management, processing, and sharing [13, 14] we will see a substantial increase in the information potential of existing and new data. In summary, we live in an exciting time of discovery during which a combination of factors enables us to leverage data collected from the living human brain in exciting and powerful ways.

Alcohol and Abstinence: Effects on Brain and Relevance to Treatment

Sara Jo Nixon—The chronic, excessive misuse of alcohol (i.e., alcoholism) is associated with significant compromise in neurobehavioral systems. An extensive literature documents

alcohol-related deficits in brain structure including both gray and white matter [15]. Studies also show altered patterns of brain activation [16, 17] and neurophysiology [18, 19]. Although prefrontal and frontal areas may be differentially sensitive, other regions are also negatively affected [15].

Critically, neuropsychological/cognitive functions are also significantly impaired. A large body of work reveals alcohol-related deficits across a variety of domains including executive function (e.g., problem-solving, behavioral inhibition, introspection, decision-making), visual-spatial functions, aspects of learning and learning, and balance/postural stability [16]. Executive functions, mediated by pre/frontal regions, appear to be more vulnerable than other domains [16, 20]. Taken together, alcoholism is associated with generalized diffuse brain dysfunction.

Given these patterns, two questions arise. The first concerns recovery of function. Importantly, improvement occurs with verbal skills recovering first, often in the first month. Other domains also demonstrate positive change across time. However, data also suggest that specific functions may not return to expected levels for months or years [19] and improvement is conditional on sustained abstinence [20].

The second question concerns the relevance of these deficits to treatment outcomes and programming. The relationship between neurocognition and treatment outcomes has been the focus of discussion for decades. Empirical studies have produced inconsistent results. Recent work by Bates and colleagues [21, 22] reveals a complex relationship influenced by interpersonal factors such as social support.

Similarly, there has been long-standing interest in whether cognitive remediation might be an active component of treatment programming [23]. Likely due to cost and staffing constraints, few studies have been conducted. Recently, there has been renewed interest and current findings indicate that cognitive training may enhance treatment processes [24, 25]. Further work is needed to determine if cognitive retraining improves sustained sobriety and adaptation.

Brain Training to Prevent and Treat Addictive Disorders

Bruce E. Wexler—Cognitive and emotion-related processes emerge from dynamically configured neural systems or networks distributed widely throughout the brain. Hubel and Wiesel were awarded the Nobel Prize for demonstrating that connections among neurons that constitute neural systems are not genetically determined, but instead are shaped, and reshaped, after birth by stimulation from the environment. It is evident, for example, in volume expansion of the right sensorimotor cortex that controls the complex fingering movements of the left hand in violin players and altered inter-regional connectivity in gymnasts. Clinicians have begun harnessing this plasticity for therapeutics; dramatically, for example, allowing blind people to see through patterns of electrical stimulation delivered to their tongues from cameras worn like eye glasses [26]. Furthermore, geriatric depressed patients who have executive dysfunction often fail to respond to medications. When these geriatric depressed patients, who failed to respond to three months of medications, were given our brain training, 90% recovered in four weeks [27]. We also have developed a

program of integrated computer-presented and physical exercises designed to activate and enhance neural systems associated with executive cognitive functions including sustained attention, working memory, cognitive flexibility and response inhibition. Used 3–4 times per week by thousands of elementary school children, gains transfer to improvement on “gold-standard” tests of focused attention, response inhibition and working memory, and to gains on school-administered tests of math and reading achievement. Children with attention deficit hyperactivity disorder (ADHD) were twice as likely to show substantial decreases in symptoms after participating in the program than during a control period of similar duration. Moreover, those who improved clinically also showed significant improvement in all administered tests of executive function, while those who did not improve clinically did not improve on any of the tests. This cognitive training approach can provide new therapeutic tools for treating individuals with a substance use disorder.

Science of Change: Prediction as a Humanitarian and Pragmatic Contribution from Human Cognitive Neuroscience

John D.E. Gabrieli—Neuroimaging has greatly enhanced the cognitive neuroscience understanding of the human brain and its variation across individuals (neurodiversity) in both health and disease. Such progress has not yet, however, propelled changes in medical practices that improve people’s lives [28]. One way in which neuroimaging may contribute is predicting what kinds of treatment are beneficial for particular patients. We reviewed [28] over seventy neuroimaging findings in which initial brain functional or structural measures (neuromarkers) correlated with or predicted future education, learning, and performance in children and adults; criminality; health-related behaviors; and responses to pharmacological or behavioral treatments. Neuromarkers often provide better predictions (neuroprognosis), alone or in combination with other measures, than traditional behavioral measures [28]. For example, clinical responses to CBT in patients with social anxiety disorder are far better predicted from baseline measures of task-activated fMRI [29] or connectomics (the combination of structural connectivity measured by diffusion weighted imaging and resting-state fMRI functional connectivity) [30] than by clinical rating scales. Variation in brain functions among adolescents correlates with future heavy use of alcohol [31, 32]. Brain measures made at the end of treatment programs for alcoholism have correlated with likelihood of future relapse (or abstinence), and were more accurate than self-reported intensity of craving or history of intake [33, 34]. Thus, neuroimaging might improve the identification of adolescents at greatest risk for alcoholism and in need of preventive treatment, or people with alcoholism who remain at high risk after treatment, and who may benefit from further treatment. With further advances in study designs and analyses, neuromarkers may offer opportunities to personalize educational and clinical practices that lead to better outcomes for people [28].

Imaging Mechanisms of Behavior Change in Motivational Interviewing

Sarah W. Feldstein Ewing, and Francesca M. Filbey—While behavior change may seem straightforward, the journey between deciding to change and fully transitioning into modified behavior is fraught with difficulties. In addition intra-individual factors can either facilitate or interfere with movement towards reduced substance use; these factors have been called “mechanisms of change” [35].

Historically examined in behavioral investigations, recent studies have extended to neurobiological factors. Here, Filbey has shown that substances that can contribute to the intractability and severity of substance use (e.g., craving) may be driven by underlying neural adaptations in key reward areas including the orbito-frontal cortex, particularly among early onset users [36, 37]; as a result, individuals may experience heightened sensitivity to substance-related cues [38].

We extended this examination of neural adaptations to the treatment context. In one intervention, motivational interviewing (MI), within-session client language has been used as a proxy to determine how “well” this treatment is working, while a treatment session is underway [39]. Work by our lab has supported that this behavioral “proxy” or “mechanism” is not only theoretically relevant, but in fact, is increasingly accumulating neurobiological support [39, 40].

Further, we have found differences in neural response to within-session client language by age group (adult versus adolescent), with adolescents showing greater activation in self-reflective regions (e.g., post cingulate gyrus/precuneus) [41] and adults showing greater involvement of key reward regions (e.g., mesocorticolimbic systems) [40]. Moreover, for adolescents, we have found that these regions of response are robust across substances of abuse (cannabis vs. alcohol) (Feldstein Ewing et al., unpublished).

In sum, these data provide some empirical substantiation of behavioral processes observed in the treatment literature. Moreover, these data support that neural manifestations of addiction and behavior change have substantial developmental variation between adolescents and adults. Thus, these data underscore the importance of specifically examining models and mechanisms of behavior change by developmental period.

Candidate Neurobiological Mechanisms of Mindfulness Meditation

Judson Brewer—Operant conditioning is one of the most evolutionarily conserved learning processes currently known in science. Its “purpose” was likely to help us remember the types of food that are calorie-rich (and which ones are poisonous) and where to find them again. Fast-forward to modern day, when food is relatively plentiful, this process gets co-opted for learning how to eat as a result of stress (as compared to hunger), smoke cigarettes, and abuse drugs. We have found that mindfulness—the ability to see behavior and the results thereof in an unbiased manner, moderates the extinction of unhealthy behaviors [42, 43]. Specifically, mindfulness training decouples the link between craving and smoking, leading to significantly increased quit rates compared to other behavioral treatments [43, 44]. In line with reinforcement of behavior, neurobiological correlates are now beginning to be mapped out [45]. In addition to typical brain pathways and regions associated with craving (e.g. mesolimbic dopaminergic system), the literature suggests that self-referential brain networks such as the default mode network (DMN), may be involved in operant conditioning [45]. Regions of the DMN, such as the posterior cingulate cortex (PCC) may be activated not necessarily by craving itself, but when individuals get “caught up in” it—the hallmark of addiction [46, 47]. Using fMRI, we have found that the PCC is deactivated in experienced meditators relative to novices, and shows increased connectivity with cognitive control regions such as the dorsolateral prefrontal cortex and the dorsal anterior cingulate

cortex [48]. Using real-time fMRI neurofeedback, we have also found in neurophenomenological studies that the subjective experience of getting caught up in experience directly corresponds to PCC activation while the opposite, letting go facilitated by mindfulness awareness, correlates with relative deactivation of the PCC [49, 50]. Taken together, these data suggest that mindfulness training targets core behavioral and brain mechanisms related to the addictive process.

Craving and the Regulation of Craving

Hedy Kober—Craving was recently added as a diagnostic criterion for addiction (DSM-5 [51]), but has long been considered a key motivating factor in drug use. Indeed, much research has shown that craving correlates with and predicts drug use as well as relapse after treatment (see [52] for review). A recent meta-analysis showed that craving predicts smoking in laboratory studies of cigarette smokers [53]. With food, we similarly showed that cue reactivity and craving predict eating and long term weight gain in the real world with a medium effect size across studies [54].

On the other hand, addiction is often conceptualized as a failure of cognitive control, with symptoms such as “using larger amounts/over longer time periods than intended”. Consistent with this, treatments that include strategies for regulating craving are effective in reducing drug use and relapse [55, 56]. Specifically, it has been shown that acquisition and application of such strategies is associated with greater abstinence [44, 57, 58].

Taken together, these data suggest that craving, the ability to regulate craving, and the neural correlates of these processes may be important mechanisms of treatment-related change and could serve as biomarkers for such change over time. We developed the Regulation of Craving (ROC) task to first investigate these processes using fMRI. Findings suggest that cognitive regulation depends on recruitment of dorsolateral and ventrolateral prefrontal cortex, and modulates activity in subcortical regions associated with craving including ventral striatum, amygdala, and subgenual anterior cingulate [59]. We continue to use the ROC in clinical trials for cigarette smoking and cocaine addiction to uncover treatment-specific neural mechanisms underlying reductions in drug use from pre- to post-treatment. One of our current hypotheses is that cognitive therapies are associated with increased “top down” regulation in prefrontal regions, whereas mindfulness-based treatments may lead to reduced “bottom up” reactivity during craving.

Imaging Mechanisms of Change: Medication Effects on Functional Connectivity during Cue-Exposure

Lara Ray and Kelly Courtney—Developing novel medications for addiction remains a high priority area. Efforts to refine and personalize the available treatments include the application of fMRI to understand the mechanisms of pharmacotherapy action. To that end, fMRI cue-reactivity paradigms represent an ideal platform to probe the involvement of neurobiological pathways subserving the reward/motivation system in addiction and potentially offer a translational mechanism by which interventions and behavioral predictions can be tested. This presentation demonstrated the utility of this approach by testing the effects of opioid blockade, via naltrexone, on fMRI measures during

methamphetamine cue-reactivity to elucidate the role of endogenous opioids in the neural systems underlying drug craving. Non-treatment seeking individuals with methamphetamine use disorders (N=23, mean age=34.7) completed a randomized, placebo-controlled, within-subject design, and underwent a visual methamphetamine cue-reactivity task during two blood-oxygen-level dependent (BOLD) fMRI sessions prior to and following three days of naltrexone (50mg) and matched placebo. fMRI analyses tested naltrexone-induced differences in BOLD activation and functional connectivity during cue processing. Naltrexone administration reduced cue-reactivity in sensorimotor regions, and altered functional connectivity of dorsal striatum, ventral tegmental area, and precuneus with frontal, visual, sensory, and motor-related regions. Naltrexone also weakened the associations between subjective craving and precuneus functional connectivity with sensorimotor regions and strengthened the associations between subjective craving and dorsal striatum and precuneus connectivity with frontal regions. This study provides the first evidence that opioidergic blockade alters neural responses to drug cues in humans with methamphetamine addiction and suggests that naltrexone may be reducing drug cue salience by decreasing the involvement of sensorimotor regions and by engaging greater frontal regulation over salience attribution. Importantly, this study demonstrates an approach to leveraging fMRI technology to advance treatment development for addiction, namely by elucidating neural mechanisms of change sub serving medication effects during exposure to drug cues.

A Self-Regulation Risk Phenotype: Implications for Treatment

Timothy J. Strauman, Bruce Luber, and Sarah H. Lisanby—To date, there has been only limited success across psychiatric disorders in matching treatments to individual variation in pathophysiology. An alternative strategy is to identify intermediate states (*risk phenotypes*) hypothesized to convey risk for a specific ‘pathway’ to disorder, and then determine whether the putative phenotype predicts vulnerability to disorder as well as response to specific treatments. We are exploring one potential transdiagnostic risk phenotype: dysfunction of *self-regulation*, defined as the psychological and neural processes that enable pursuit of personal goals. Our approach is based on regulatory focus theory [60], a model of the cognitive-motivational systems underlying goal pursuit that distinguishes between strategic approach (promotion) and strategic avoidance (prevention). Chronic promotion goal pursuit failure is discriminately associated with depressive symptoms [61], and depression is associated with attenuated left PFC activation in response to promotion goal priming [62]. Previously, we developed self-system therapy (SST), a brief structured psychotherapy targeting self-regulatory problems that has shown specific efficacy for individuals characterized by regulatory system dysfunction [63]. We have begun to extend this model to consider whether the neural circuits associated with promotion system dysfunction can be modulated therapeutically using repetitive transcranial magnetic stimulation (rTMS). In particular, we are exploring whether individually targeted neurostimulation can be paired effectively with intentional engagement of promotion-related cognition. We are using fMRI to identify, on an individual basis, left PFC sites (Brodmann areas 9/10) which are maximally responsive to promotion goal priming. Our hypothesis is that increasing specifically targeted left PFC activation during intentional engagement of promotion-related cognition by simultaneous use of rTMS and SST will reduce depression

by facilitating more effective promotion system function. Initial findings suggest that this combined treatment approach is feasible, safe, and may be a tool for delineating a self-regulation risk phenotype for depression and other disorders.

Novel Approaches to Assessing Motivation among those seeking AUD Treatment

Jon Morgenstern—Motivation to reduce or quit drinking is a key component of the AUD treatment process and a common target of most evidence-based AUD treatments [64]. Building on prior work in cognitive science, this study developed an implicit cognition task and an ecological momentary assessment (EMA) task to assess motivation to reduce drinking and examined their psychometric properties, including their ability to predict subsequent drinking. Implicit alcohol approach and avoidance tendencies were assessed using a modified version of the Stimulus Compatibility Response (SCR: [65]) task. Daily ratings of commitment to not drink heavily were assessed as part of a twice daily survey delivered via a smartphone. Problem drinkers (N=60) completed the measures at baseline, during, and at end of the 8-week treatment period. Baseline approach and avoidance significantly predicted three-month drinking outcomes, explaining an additional 12% of variance in outcome over baseline drinking. Daily commitment to not drink heavily was a significant predictor of next day's drinking, even after controlling for prior drinking. Readiness to change [66], a standard measure used to assess motivation in AUD treatment research, was not a significant predictor of drinking outcomes in any analysis. In addition, the implicit cognition and EMA measures were weakly associated with other commonly used treatment process measures such as self-efficacy and coping. Finally, the implicit cognition and EMA measures were unique predictors of drinking outcome when entered simultaneously in a regression analysis. Findings suggest that motivation to reduce drinking is a multi-faceted construct and that future research should examine ways to decompose motivation to its component parts. Future research also should include the use of neuroimaging to probe neural substrates associated with motivational processes identified in this study. Overall, findings strongly support the use of novel approaches including cognitive neuroscience to advance the study of mechanisms of behavior change in AUD [67–69].

Conclusions

Neuroimaging studies, in contrast to behavioral research [1], have begun to identify therapy-specific mechanisms of action. For example, CBT strengthens cognitive control circuitry, whereas mindfulness may act primarily by reducing the salience of reward cues. Behavioral treatments, however, involve multiple components and mechanisms. For example, other models of mindfulness have proposed brain mechanisms (e.g., PCC activation) that are being targeted in neurofeedback, or have proposed that MBRP impacts neuro-inflammatory and epigenetic mechanisms, in addition to brain circuitry. Other interventions, such as cognitive training, target specific aberrations in brain functioning to “tune up” circuits affected by heavy substance use.

The models of brain mechanisms that were presented highlight key issues in a nascent field: the challenge of more precisely specifying “how” and “for whom” treatment works at the level of the brain; complexities in determining the effects of treatment in the context of

recovery of brain functioning that occurs with abstinence; the need for valid research methods and novel analytic strategies; determination of the “added value” of neuromarkers in predicting and monitoring response to treatment [70]; the influence of development (adolescent versus adult), co-occurring psychopathology, and a disorder’s dynamic course on brain mechanisms; and comparison of brain mechanisms underlying medication and behavioral treatment effects, for example, on craving and cue reactivity across addictive behaviors. Importantly, the conceptual models invoke transdiagnostic concepts of cognitive control, reward processing, and self-regulation; and consider individual differences, in moving toward “personalized medicine” [71].

Future directions include refining multi-modal approaches to treatment, in which the same neural circuitry is targeted for intervention by carefully selected combinations of psychotherapy, neuromodulation (e.g., rTMS, tDCS), and medication, to amplify and accelerate treatment effects. Another direction involves identifying brain mechanisms underlying implicit cognitions [72], a novel predictor of treatment outcome. Despite evidence of promise, the use of brain imaging for clinical applications faces limitations such as high cost. Nevertheless, neuroimaging provides powerful tools for identifying brain mechanisms that drive and sustain therapeutic change, and for determining for whom an intervention will be effective.

Videos of the presentations in this article can be accessed at: www.scienceofchange.org

Acknowledgments

We thank Dr Bob Huebner for the inspiration for the meeting, and for his enthusiastic support of this conference series. The 2015 Science of Change meeting, “Neuroimaging mechanisms of change in psychotherapy for addictive behaviors”, was held as a satellite to the Research Society on Alcoholism annual meeting in San Antonio, TX.

Support: National Institute on Alcohol Abuse and Alcoholism R13 AA023455

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance
- 1. Black JJ, Chung T. Mechanisms of change in adolescent substance use treatment: how does treatment work? *Subst Abus.* 2014; 35(4):344–51. Review of behavioral studies of mechanisms of change in adolescent substance use treatment, which similar to reviews of behavioral research on mechanisms of change in adult addictions treatment, found greater support for “common” rather than “therapy-specific” mechanisms of change across distinct types of treatment. [PubMed: 24901750]
- 2. Feldstein Ewing SW, Chung T. Neuroimaging mechanisms of change in psychotherapy for addictive behaviors: emerging translational approaches that bridge biology and behavior. *Psychol Addict Behav.* 2013; 27(2):329–35. Introduction to a journal special issue on brain mechanisms of change in behavioral treatment for addictive behaviors. [PubMed: 23815447]
- 3. Potenza MN, Sofuoglu M, Carroll KM, Rounsaville BJ. Neuroscience of behavioral and pharmacological treatments for addictions. *Neuron.* 2011; 69(4):695–712. Review article on neurobiology of behavioral and pharmacologic interventions for addictive behaviors. [PubMed: 21338880]

- 4. Sullivan EV, Noronha A. Translating alcohol research into practice. *Alc Res: Curr Rev.* 2015; 37:1–3. Introduction to a journal issue that reviews recent findings from brain research relevant to prevention and treatment of alcohol use disorder.
5. Calhoun VD, Miller R, Pearlson G, Adali T. The chronnectome: time-varying connectivity networks as the next frontier in fMRI data discovery. *Neuron.* 2014; 84(2):262–74. [PubMed: 25374354]
6. Vergara, V.; Weiland, B.; Hutchison, K.; Calhoun, VD., editors. Dynamic Functional Network Connectivity in the Brain of Nicotine and Alcohol Users. Annual Meeting of the Organization for Human Brain Mapping; 2015; Honolulu, HI.
7. Vergara, V.; Mayer, A.; Calhoun, VD., editors. The Impact of Data Preprocessing in Traumatic Brain Injury Diagnosis using Functional Magnetic Resonance Imaging. EMBC; 2015; Milan, Italy.
8. Silva, R.; Castro, E.; Gupta, N.; Cetin, M.; Arbabshirani, M.; Potluru, V., et al., editors. The Tenth Annual MLSP Competition: Schizophrenia Classification Challenge. IEEE International Workshop on Machine Learning for Signal Processing; 2014; Reims, France.
9. Sui J, Yu Q, He H, Calhoun VD. A Selective Review of Multimodal Fusion Methods in Schizophrenia. *Frontiers in Human Neuroscience.* 2013; 6(27)
10. Plis SM, Hjelm DR, Salakhutdinov R, Allen EA, Bockholt HJ, Long JD, et al. Deep learning for neuroimaging: a validation study. *Front Neurosci.* 2014; 8:229. [PubMed: 25191215]
11. Amin, F.; Plis, S.; Damaraju, E.; Hjelm, D.; Cho, K.; Calhoun, VD., editors. A deep-learning approach to translate between brain structure and brain function. Pattern Recognition in NeuroImaging (PRNI); 2015; Palo Alto, CA.
12. Eickhoff S, Nichols TE, Van Horn JD, Turner JA. Sharing the wealth: Neuroimaging data repositories. *Neuroimage.* 2016; 124(Pt B):1065–8. [PubMed: 26574120]
13. King MD, Wood D, Miller B, Kelly R, Landis D, Courtney W, et al. Automated collection of imaging and phenotypic data to centralized and distributed data repositories. *Front Neuroinform.* 2014; 8(60):60. [PubMed: 24926252]
14. Wood D, King M, Landis D, Courtney W, Wang R, Kelly R, et al. Harnessing modern web application technology to create intuitive and efficient data visualization and sharing tools. *Front Neuroinform.* 2014; 8(71):71. [PubMed: 25206330]
15. Pfefferbaum A, Rosenbloom MJ, Fama R, Sassoon SA, Sullivan EV. Transcallosal white matter degradation detected with quantitative fiber tracking in alcoholic men and women: selective relations to dissocial functions. *Alcohol Clin Exp Res.* 2010; 34(7):1201–11. [PubMed: 20477772]
16. Oscar-Berman M, Marinkovic K. Alcohol: effects on neurobehavioral functions and the brain. *Neuropsychol Rev.* 2007; 17(3):239–57. [PubMed: 17874302]
17. Zahr NM, Kaufman KL, Harper CG. Clinical and pathological features of alcohol-related brain damage. *Nat Rev Neurol.* 2011; 7(5):284–94. [PubMed: 21487421]
18. Rangaswamy, M.; Porjesz, B. Understanding alcohol use disorders with neuroelectrophysiology. In: Sullivan, EV.; Pfefferbaum, A., editors. Handbook of Clinical Neurology. Vol. 125. Waltham, MA: Elsevier, B.V; 2014. p. 383-414.
19. Fein G, Cardenas VA. Neuroplasticity in Human Alcoholism: Studies of Extended Abstinence with Potential Treatment Implications. *Alcohol Res.* 2015; 37(1):125–41. [PubMed: 26259093]
20. Pitel, AL.; Eustache, F.; Beaunieux, H. Component processes of memory in alcoholism: pattern of compromise and neural substrates. In: Sullivan, EV.; Pfefferbaum, A., editors. Handbook of Clinical Neurology. Vol. 125. Waltham, MA: Elsevier B.V; 2014. p. 211-25.
21. Bates ME, Pawlak AP, Tonigan JS, Buckman JF. Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change. *Psychol Addict Behav.* 2006; 20(3):241–53. [PubMed: 16938062]
22. Buckman JF, Bates ME, Morgenstern J. Social support and cognitive impairment in clients receiving treatment for alcohol- and drug-use disorders: a replication study. *J Stud Alcohol Drugs.* 2008; 69(5):738–46. [PubMed: 18781249]
23. Goldman MS. Cognitive impairment in chronic alcoholics. Some cause for optimism. *Am Psychol.* 1983; 38(10):1045–54. [PubMed: 6357006]
24. Houben K, Wiers RW, Jansen A. Getting a grip on drinking behavior: training working memory to reduce alcohol abuse. *Psychol Sci.* 2011; 22(7):968–75. [PubMed: 21685380]

25. Rupp CI, Kemmler G, Kurz M, Hinterhuber H, Fleischhacker WW. Cognitive remediation therapy during treatment for alcohol dependence. *J Stud Alcohol Drugs*. 2012; 73(4):625–34. [PubMed: 22630801]
26. Nau AC, Pintar C, Arnoldussen A, Fisher C. Acquisition of Visual Perception in Blind Adults Using the BrainPort Artificial Vision Device. *Am J Occup Ther*. 2015; 69(1):6901290010p1–8.
27. Morimoto SS, Wexler BE, Liu J, Hu W, Seirup J, Alexopoulos GS. Neuroplasticity-based computerized cognitive remediation for treatment-resistant geriatric depression. *Nat Commun*. 2014; 5:4579. [PubMed: 25093396]
- 28. Gabrieli JD, Ghosh SS, Whitfield-Gabrieli S. Prediction as a humanitarian and pragmatic contribution from human cognitive neuroscience. *Neuron*. 2015; 85(1):11–26. Review of neuroimaging research on the use of brain functional or structural measures (neuromarkers) as predictors of educational, health, and treatment outcomes in youth and adults. [PubMed: 25569345]
29. Doehrmann O, Ghosh SS, Polli FE, Reynolds GO, Horn F, Keshavan A, et al. Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. *JAMA Psychiatry*. 2013; 70(1):87–97. [PubMed: 22945462]
30. Whitfield-Gabrieli S, Ghosh SS, Nieto-Castanon A, Saygin Z, Doehrmann O, Chai XJ, et al. Brain connectomics predict response to treatment in social anxiety disorder. *Mol Psychiatry*. 2015
31. Norman AL, Pulido C, Squeglia LM, Spadoni AD, Paulus MP, Tapert SF. Neural activation during inhibition predicts initiation of substance use in adolescence. *Drug Alcohol Depend*. 2011; 119(3):216–23. [PubMed: 21782354]
32. Stice E, Yokum S, Burger KS. Elevated reward region responsivity predicts future substance use onset but not overweight/obesity onset. *Biol Psychiatry*. 2013; 73(9):869–76. [PubMed: 23312561]
33. Grusser SM, Wrase J, Klein S, Hermann D, Smolka MN, Ruf M, et al. Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. *Psychopharmacology (Berl)*. 2004; 175(3):296–302. [PubMed: 15127179]
34. Braus DF, Wrase J, Grusser S, Hermann D, Ruf M, Flor H, et al. Alcohol-associated stimuli activate the ventral striatum in abstinent alcoholics. *J Neural Transm (Vienna)*. 2001; 108(7):887–94. [PubMed: 11515754]
35. Morgenstern J, Kuerbis A, Amrhein P, Hail L, Lynch K, McKay JR. Motivational interviewing: a pilot test of active ingredients and mechanisms of change. *Psychol Addict Behav*. 2012; 26(4):859–69. [PubMed: 22905896]
- 36. Filbey FM, Aslan S, Calhoun VD, Spence JS, Damaraju E, Caprihan A, et al. Long-term effects of marijuana use on the brain. *Proc Natl Acad Sci U S A*. 2014; 111(47):16913–8. Study comparing marijuana users and controls, which found that marijuana users had greater functional connectivity in orbitofrontal cortex network, which was associated with earlier age of marijuana use onset. Results suggest complex neuroadaptive processes associated with long-term marijuana use. [PubMed: 25385625]
37. Filbey FM, McQueeney T, DeWitt SJ, Mishra V. Preliminary findings demonstrating latent effects of early adolescent marijuana use onset on cortical architecture. *Dev Cogn Neurosci*. 2015
38. Filbey FM, Dunlop J. Differential reward network functional connectivity in cannabis dependent and non-dependent users. *Drug Alcohol Depend*. 2014; 140:101–11. [PubMed: 24838032]
- 39. Feldstein Ewing SW, Filbey FM, Hendershot CS, McEachern AD, Hutchison KE. Proposed model of the neurobiological mechanisms underlying psychosocial alcohol interventions: the example of motivational interviewing. *J Stud Alcohol Drugs*. 2011; 72(6):903–16. This article describes a model of brain mechanisms underlying effects of motivational interviewing. [PubMed: 22051204]
40. Feldstein Ewing SW, Filbey FM, Sabbineni A, Chandler LD, Hutchison KE. How psychosocial alcohol interventions work: a preliminary look at what FMRI can tell us. *Alcohol Clin Exp Res*. 2011; 35(4):643–51. [PubMed: 21223301]
41. Feldstein Ewing SW, McEachern AD, Yezhuvath U, Bryan AD, Hutchison KE, Filbey FM. Integrating brain and behavior: evaluating adolescents' response to a cannabis intervention. *Psychol Addict Behav*. 2013; 27(2):510–25. [PubMed: 22925010]

42. Brewer JA, Elwafi HM, Davis JH. Craving to quit: psychological models and neurobiological mechanisms of mindfulness training as treatment for addictions. *Psychol Addict Behav.* 2013; 27(2):366–79. [PubMed: 22642859]
- 43. Elwafi HM, Witkiewitz K, Mallik S, Thornhill TAt, Brewer JA. Mindfulness training for smoking cessation: moderation of the relationship between craving and cigarette use. *Drug Alcohol Depend.* 2013; 130(1–3):222–9. This was the first study to show that mindfulness training directly targets core behavioral learning processes implicated in addictive behavior, namely operant conditioning. It specifically showed that mindfulness decoupled the link between craving and smoking. [PubMed: 23265088]
- 44. Brewer JA, Mallik S, Babuscio TA, Nich C, Johnson HE, Deleone CM, et al. Mindfulness training for smoking cessation: results from a randomized controlled trial. *Drug Alcohol Depend.* 2011; 119(1–2):72–80. This was the first study to show the efficacy of mindfulness training for smoking cessation. Mindfulness training was found to have significantly increased efficacy compared to “gold standard” behavioral treatment. [PubMed: 21723049]
45. Brewer JA, Davis JH, Goldstein J. Why is it so hard to pay attention, or is it? Mindfulness, the factors of awakening and reward-based learning. *Mindfulness (N Y).* 2013; 4(1)
46. Brewer JA, Garrison KA, Whitfield-Gabrieli S. What about the “Self” is Processed in the Posterior Cingulate Cortex? *Front Hum Neurosci.* 2013; 7:647. [PubMed: 24106472]
47. Brewer JA, Garrison KA. The posterior cingulate cortex as a plausible mechanistic target of meditation: findings from neuroimaging. *Ann N Y Acad Sci.* 2014; 1307:19–27. [PubMed: 24033438]
- 48. Brewer JA, Worhunsky PD, Gray JR, Tang YY, Weber J, Kober H. Meditation experience is associated with differences in default mode network activity and connectivity. *Proc Natl Acad Sci U S A.* 2011; 108(50):20254–9. This was the first study to show altered brain activity and connectivity in experienced meditators across a number of different meditation techniques. It specifically showed altered default mode network activity and connectivity in experts. [PubMed: 22114193]
- 49. Garrison KA, Scheinost D, Worhunsky PD, Elwafi HM, Thornhill TAt, Thompson E, et al. Real-time fMRI links subjective experience with brain activity during focused attention. *Neuroimage.* 2013; 81:110–8. This was the first study to show that real-time fMRI neurofeedback could be used to link subjective experience with brain activity. [PubMed: 23684866]
- 50. Garrison KA, Santoyo JF, Davis JH, Thornhill TAt, Kerr CE, Brewer JA. Effortless awareness: using real time neurofeedback to investigate correlates of posterior cingulate cortex activity in meditators’ self-report. *Front Hum Neurosci.* 2013; 7:440. This was the first neurophenomenological study of meditation that identified posterior cingulate activity as directly correlated with “getting caught up” in behavior (increased activity), and “letting go” (decreased activity) through mindful awareness. [PubMed: 23964222]
51. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5. Washington, D.C: American Psychiatric Association; 2012. DSM-5
52. Kober, H.; Mell, MM. Neural Mechanisms Underlying Craving and the Regulation of Craving. In: Wilson, SJ., editor. *The Wiley Handbook on the Cognitive Neuroscience of Addiction.* Oxford, UK: Wiley & Sons; 2015. p. 195–218.
53. Gass JC, Motschman CA, Tiffany ST. The relationship between craving and tobacco use behavior in laboratory studies: a meta-analysis. *Psychol Addict Behav.* 2014; 28(4):1162–76. [PubMed: 25134054]
54. Boswell RG, Kober H. Food Cue Reactivity and Craving Predict Eating and Weight Gain: A Meta-Analytic Review. *Obesity Reviews.* In press.
- 55. Carroll, KM. *A Cognitive-Behavioral Approach: Treating Cocaine Addiction.* Rockville, MD: National Institute of Drug Abuse; 1998. Treatment manual for Cognitive-Behavioral Therapy in Addiction, including sections on regulation of craving. Instructions in the original ROC task (Kober et al., 2010) are modeled after the strategies in this manual
56. Carroll KM, Nich C, Ball SA, McCance E, Frankforter TL, Rounsaville BJ. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. *Addiction.* 2000; 95(9):1335–49. [PubMed: 11048353]

57. Kiluk BD, Nich C, Babuscio T, Carroll KM. Quality versus quantity: acquisition of coping skills following computerized cognitive behavioral therapy for substance use disorders. *Addiction*. 2010; 105(12):2120–7. [PubMed: 20854334]
58. O'Connell KA, Hosein VL, Schwartz JE, Leibowitz RQ. How does coping help people resist lapses during smoking cessation? *Health Psychol*. 2007; 26(1):77–84. [PubMed: 17209700]
59. Kober H, Mende-Siedlecki P, Kross EF, Weber J, Mischel W, Hart CL, et al. Prefrontal-striatal pathway underlies cognitive regulation of craving. *Proc Natl Acad Sci U S A*. 2010; 107(33): 14811–6. [PubMed: 20679212]
- 60. Higgins ET. Beyond pleasure and pain. *Am Psychol*. 1997; 52(12):1280–300. This is the original version of the Regulation of Craving (ROC) task. Findings suggest that cognitive regulation depend on recruitment of dorsolateral and ventrolateral prefrontal cortex, and modulate activity in subcortical regions associated with craving including ventral striatum, amygdala, and subgenual anterior cingulate. [PubMed: 9414606]
61. Strauman TJ. Self-guides, autobiographical memory, and anxiety and dysphoria: toward a cognitive model of vulnerability to emotional distress. *J Abnorm Psychol*. 1992; 101(1):87–95. [PubMed: 1537978]
62. Eddington KM, Dolcos F, McLean AN, Krishnan KR, Cabeza R, Strauman TJ. Neural correlates of idiographic goal priming in depression: goal-specific dysfunctions in the orbitofrontal cortex. *Soc Cogn Affect Neurosci*. 2009; 4(3):238–46. [PubMed: 19433416]
63. Strauman TJ, Vieth AZ, Merrill KA, Kolden GG, Woods TE, Klein MH, et al. Self-system therapy as an intervention for self-regulatory dysfunction in depression: a randomized comparison with cognitive therapy. *J Consult Clin Psychol*. 2006; 74(2):367–76. [PubMed: 16649881]
64. Longabaugh, R.; Magill, M.; Morgenstern, J.; Huebner, R. Mechanisms of behavior change in treatment for alcohol and other drug use disorders. In: McCrady, BS.; Epstein, EE., editors. *Addictions: A comprehensive guidebook*. New York: Oxford University Press; 2014. p. 572-96.
65. Field M, Kiernan A, Eastwood B, Child R. Rapid approach responses to alcohol cues in heavy drinkers. *J Behav Ther Exp Psychiatry*. 2008; 39(3):209–18. [PubMed: 17640615]
66. Heather N, Rollnick S. Readiness to change questionnaire: User's manual. 2000
67. Morgenstern J, Naqvi NH, Debellis R, Breiter HC. The contributions of cognitive neuroscience and neuroimaging to understanding mechanisms of behavior change in addiction. *Psychol Addict Behav*. 2013; 27(2):336–50. [PubMed: 23586452]
68. Naqvi NH, Morgenstern J. Cognitive Neuroscience Approaches to Understanding Behavior Change in Alcohol Use Disorder Treatments. *Alcohol Res*. 2015; 37(1):29–38. [PubMed: 26259087]
69. Morgenstern J, Kuerbis A, Muench F. Ecological Momentary Assessment and Alcohol Use Disorder Treatment. *Alcohol Res*. 2014; 36(1):101–9. [PubMed: 26259004]
70. Heilig M, Leggio L. What the alcohol doctor ordered from the neuroscientist: Theragnostic biomarkers for personalized treatments. *Progress in Brain Research*. (online 10-27-15).
71. Litten RZ, Ryan ML, Falk DE, Reilly M, Fertig JB, Koob GF. Heterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment. *Alcohol Clin Exp Res*. 2015; 39:579–84. [PubMed: 25833016]
- 72. Fadardi JS, Cox WM, Rahman A. Neuroscience of attentional processes for addiction medicine: From brain mechanisms to practical considerations. *Progress in Brain Research*. (online 11-23-15). This review outlines a Research Domain Criteria (RDoC) framework for alcohol use disorder to guide research that will inform personalized treatment and “precision medicine”.

Figure 1.
Proposed model for studying brain mechanisms of change in psychotherapy for addictive behaviors (Kathleen M. Carroll)

Figure 2.

Proposed mediation model of treatment effects on drinking outcomes (Kent Hutchison)

Notes: MBRP= Mindfulness Based Relapse Prevention, RP=Relapse Prevention